Ratner Lab

Publications

Raut, NG; Maile, LA; Oswalt, LM; Mitxelena, I; Adlakha, A; Sprague, KL; Rupert, AR; Bokros, L; Hofmann, MC; Patritti-Cram, J; et al. Schwann cells modulate nociception in neurofibromatosis 1. JCI insight. 2024; 9:e171275.

Pillay-Smiley, N; Fletcher, JS; de Blank, P; Ratner, N. Shedding New Light: Novel Therapies for Common Disorders in Children with Neurofibromatosis Type I. Pediatric Clinics of North America. 2023; 70:937-950.

Gonzalez-Muñoz, T; Giannatale, AD; García-Silva, S; Santos, V; Sanchez-Redondo, S; Savini, C; Graña-Castro, O; Blanco-Aparicio, C; Fischer, S; De Wever, O; et al. Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis. Clinical Cancer Research. 2023; 29:3744-3758.

Wang, C; Tu, Z; Cai, X; Wang, W; Davis, AK; Nattamai, K; Paranjpe, A; Dexheimer, P; Wu, J; Huang, FL; et al. A critical role of RUNX1 in governing megakaryocyte-primed hematopoietic stem cell differentiation. Blood Advances. 2023; 7:2590-2605.

Doherty, AC; Huddleston, DA; Horn, PS; Ratner, N; Simpson, BN; Schorry, EK; Aschbacher-Smith, L; Prada, CE; Gilbert, DL. Motor Function and Physiology in Youth With Neurofibromatosis Type 1. Pediatric Neurology. 2023; 143:34-43.

Jackson, M; Ahmari, N; Wu, J; Rizvi, TA; Fugate, E; Kim, MO; Dombi, E; Arnhof, H; Boehmelt, G; Düchs, MJ; et al. Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage. The Journal of pharmacology and experimental therapeutics. 2023; 385:106-116.

Ratner, N; Hu, L; Pundavela, J; Epstein, JA. Abstract IA17: Use of RAS isoforms in nerve tumors. Molecular cancer research : MCR. 2023; 21:ia17.

Na, Y; Hall, A; Yu, Y; Hu, L; Choi, K; Burgard, JA; Szabo, S; Huang, G; Ratner, N; Wu, J. Runx1/3-driven adaptive endoplasmic reticulum stress pathways contribute to neurofibromagenesis. Oncogene: Including Oncogene Reviews. 2023; 42:1038-1047.

Hennigan, RF; Thomson, CS; Stachowski, K; Nassar, N; Ratner, N. Merlin tumor suppressor function is regulated by PIP2-mediated dimerization. Editor, van der Wel P. PloS one. 2023; 18:e0281876.

Magallón-Lorenz, M; Terribas, E; Ortega-Bertran, S; Creus-Bachiller, E; Fernández, M; Requena, G; Rosas, I; Mazuelas, H; Uriarte-Arrazola, I; Negro, A; et al. Deep genomic analysis of malignant peripheral nerve sheath tumor cell lines challenges current malignant peripheral nerve sheath tumor diagnosis. iScience. 2023; 26:106096.

Kershner, LJ; Choi, K; Wu, J; Zhang, X; Perrino, M; Salomonis, N; Shern, JF; Ratner, N. Multiple Nf1 Schwann cell populations reprogram the plexiform neurofibroma tumor microenvironment. JCI insight. 2022; 7:e154513.

González-Muñoz, T; Kim, AR; Ratner, N; Peinado, H. The Need for New Treatments Targeting MPNST: The Potential of Strategies Combining MEK Inhibitors with Antiangiogenic Agents. Clinical Cancer Research. 2022; 28:3185-3195.

Cram, JP; Wu, J; Coover, RA; Rizvi, TA; Chaney, KE; Ravindran, R; Cancelas, JA; Spinner, RJ; Ratner, N. P2RY14 cAMP signaling regulates Schwann cell precursor self-renewal, proliferation, and nerve tumor initiation in a mouse model of neurofibromatosis. eLife. 2022; 11:e73511.

Chaney, KE; Perrino, MR; Kershner, LJ; Patel, AV; Wu, J; Choi, K; Rizvi, TA; Dombi, E; Szabo, S; Largaespada, DA; et al. Cdkn2a Loss in a Model of Neurofibroma Demonstrates Stepwise Tumor Progression to Atypical Neurofibroma and MPNST. Cancer Research. 2021; 80:4720-4730.

Heinrich, A; Bhandary, B; Potter, SJ; Ratner, N; DeFalco, T. Cdc42 activity in Sertoli cells is essential for maintenance of spermatogenesis. Cell Reports. 2021; 37:109885.

Patritti-Cram, J; Coover, RA; Jankowski, MP; Ratner, N. Purinergic signaling in peripheral nervous system glial cells. Glia. 2021; 69:1837-1851.

Thomson, CS; Pundavela, J; Perrino, MR; Coover, RA; Choi, K; Chaney, KE; Rizvi, TA; Largaespada, DA; Ratner, N. WNT5A inhibition alters the malignant peripheral nerve sheath tumor microenvironment and enhances tumor growth. Oncogene: Including Oncogene Reviews. 2021; 40:4229-4241.

Galvin, R; Watson, AL; Largaespada, DA; Ratner, N; Osum, S; Moertel, CL. Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib. Current Oncology Reports. 2021; 23:45.

Vélez-Reyes, GL; Koes, N; Ryu, JH; Kaufmann, G; Berner, M; Weg, MT; Wolf, NK; Rathe, SK; Ratner, N; Moriarity, BS; et al. Transposon Mutagenesis-Guided CRISPR/Cas9 Screening Strongly Implicates Dysregulation of Hippo/YAP Signaling in Malignant Peripheral Nerve Sheath Tumor Development. Cancers. 2021; 13:1584.

Weiss, BD; Wolters, PL; Plotkin, SR; Widemann, BC; Tonsgard, JH; Blakeley, J; Allen, JC; Schorry, E; Korf, B; Robison, NJ; et al. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. Journal of Clinical Oncology. 2021; 39:797-806.

Oatman, N; Dasgupta, N; Arora, P; Choi, K; Gawali, MV; Gupta, N; Parameswaran, S; Salomone, J; Reisz, JA; Lawler, S; et al. Mechanisms of stearoyl CoA desaturase inhibitor sensitivity and acquired resistance in cancer. Science Advances. 2021; 7:eabd7459.

Na, Y; Hall, A; Choi, K; Hu, L; Rose, J; Coover, RA; Miller, A; Hennigan, RF; Dombi, E; Kim, MO; et al. MicroRNA-155 contributes to plexiform neurofibroma growth downstream of MEK. Oncogene: Including Oncogene Reviews. 2021; 40:951-963.

Ma, Y; Gross, AM; Dombi, E; Pemov, A; Choi, K; Chaney, K; Rhodes, SD; Angus, SP; Sciaky, N; Clapp, DW; et al. A molecular basis for neurofibroma-associated skeletal manifestations in NF1. Genetics in Medicine. 2020; 22:1786-1793.

Asleh, J; Shofty, B; Cohen, N; Kavushansky, A; Lopez-Juarez, A; Constantini, S; Ratner, N; Kahn, I. Brain-wide structural and functional disruption in mice with oligodendrocyte-specific Nf1 deletion is rescued by inhibition of nitric oxide synthase. Proceedings of the National Academy of Sciences of USA. 2020; 117:22506-22513.

Fletcher, JS; Pundavela, J; Ratner, N. After Nf1 loss in Schwann cells, inflammation drives neurofibroma formation. Neuro-Oncology Advances. 2020; 2:i23-i32.

Palomo-Irigoyen, M; Pérez-Andrés, E; Iruarrizaga-Lejarreta, M; Barreira-Manrique, A; Tamayo-Caro, M; Vila-Vecilla, L; Moreno-Cugnon, L; Beitia, N; Medrano, D; Fernández-Ramos, D; et al. HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis. The Journal of Clinical Investigation. 2020; 130:3848-3864.

Heinrich, A; Potter, SJ; Guo, L; Ratner, N; DeFalco, T. Distinct Roles for Rac1 in Sertoli Cell Function during Testicular Development and Spermatogenesis. Cell Reports. 2020; 31:107513.

Guo, J; Chaney, KE; Choi, K; Witek, G; Patel, AV; Xie, H; Lin, D; Whig, K; Xiong, Y; Schultz, DC; et al. Polo-like kinase 1 as a therapeutic target for malignant peripheral nerve sheath tumors (MPNST) and schwannomas. American Journal of Cancer Research. 2020; 10:856-869.

Gripp, KW; Schill, L; Schoyer, L; Stronach, B; Bennett, AM; Blaser, S; Brown, A; Burdine, R; Burkitt-Wright, E; Castel, P; et al. The sixth international RASopathies symposium: Precision medicine-From promise to practice. American Journal of Medical Genetics, Part A. 2020; 182:597-606.

Yokota, A; Huo, L; Lan, F; Wu, J; Huang, G. The Clinical, Molecular, and Mechanistic Basis of RUNX1 Mutations Identified in Hematological Malignancies. MOLECULES AND CELLS. 2020; 43:145-152.

Na, Y; Huang, G; Wu, J. The Role of RUNX1 in NF1-Related Tumors and Blood Disorders. MOLECULES AND CELLS. 2020; 43:153-159.

Yu, Y; Choi, K; Wu, J; Andreassen, PR; Dexheimer, PJ; Keddache, M; Brems, H; Spinner, RJ; Cancelas, JA; Martin, LJ; et al. NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation. Acta Neuropathologica. 2020; 139:157-174.